Interaction between Asian/non-Asian and primary efficacy end point ( a composite of vascular death , myocardial infarction , and stroke ) and net clinical benefit ( composite of primary efficacy end point and coronary artery bypass graft [ CABG ] surgery or non-CABG-related major bleeding ) were evaluated with a Cox proportional hazards model .